What to Expect From Bristol-Myers Squibb's Q2 2025 Earnings Report
/Bristol-Myers%20Squibb%20Co_%20NJ%20office-by%20Amy%20Lutz%20via%20Shutterstock.jpg)
Bristol-Myers Squibb Company (BMY) is one of the leading biopharmaceutical companies focused on developing treatments for diseases like cancer, inflammatory, immunologic, cardiovascular, or fibrotic diseases. With a market cap of $95.4 billion, Bristol-Myers’ operations span various countries in the Americas, Europe, and the Indo-Pacific.
The healthcare giant is expected to announce its second-quarter results before the market opens on Thursday, Jul. 31. Ahead of the event, analysts expect BMY to deliver a profit of $1.38 per share, down 33.3% from $2.07 per share reported in the year-ago quarter. On a positive note, the company has a solid earnings surprise history and has surpassed the Street’s bottom-line estimates in each of the past four quarters.
For the full fiscal 2025, analysts expect BMY to deliver an EPS of $6.56, significantly up from $1.15 reported in the previous year. While in fiscal 2026, its earnings are expected to drop 8.1% year-over-year to $6.03 per share.
BMY stock prices have gained nearly 15% over the past 52 weeks, outpacing the S&P 500 Index’s ($SPX) 12.1% gains and the Health Care Select Sector SPDR Fund’s (XLV) 8.3% decline during the same time frame.
Bristol-Myers Squibb’s stock prices observed a marginal uptick in the trading session after the release of its better-than-expected Q1 results on Apr. 24. Due to a drop in US sales and currency headwinds faced in foreign markets, the company’s overall topline for the quarter dropped 5.6% year-over-year to $11.2 billion. However, these figures surpassed the Street’s expectations by a notable margin. Meanwhile, the company reported an adjusted net income of $3.7 billion, up from the $8.2 billion loss reported in the year-ago quarter. Moreover, its adjusted EPS of $1.80 surpassed the consensus estimates by 19.2%.
The stock holds a consensus “Moderate Buy” rating overall. Of the 26 analysts covering the BMY stock, opinions include seven “Strong Buys,” 18 “Holds,” and one “Strong Sell.” Its mean price target of $56.05 suggests a 19.6% upside potential from current price levels.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.